Long‐term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial
Cancer · 2025
DOI: 10.1002/cncr.70150 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer, 2025. Verfasst von Jun Zhang und 31 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Sunitinib, Gastrointestinal Neoplasms. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
In a bridging study of INTRIGUE, second‐line ripretinib demonstrated comparable progression‐free survival (PFS) and favorable safety versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor. Overall survival (OS) was highly immature at the time of primary analysis. This updated analysis assessed long‐term OS of ripretinib versus sunitinib.
Methods
This phase 2, multicenter, randomized, open‐label study in China enrolled patients with gastrointestinal stromal tumor previously treated with imatinib, randomized (1:1) to ripretinib 150 mg once daily by continuous dosing in 42‐day cycles or sunitinib 50 mg once daily in 42‐day cycles (four weeks on/two weeks off). The updated analysis assessed OS and PFS on third‐line therapy in all‐patient intention‐to‐treat and KIT exon 11‐mutated intention‐to‐treat (Ex11 ITT) populations.
Results
Of 108 patients randomized, 54 received ripretinib and 54 sunitinib; 70 had a primary KIT exon 11 mutation (ripretinib, n = 35; sunitinib, n = 35; Ex11 ITT). By December 30, 2024, in all‐patient intention‐to‐treat population, median OS was 43.3 months with ripretinib and 29.9 months with sunitinib (hazard ratio, 0.681; 95% CI, 0.411–1.126; nominal p = .134). In the Ex11 ITT population, median OS was 43.3 months with ripretinib and 28.6 months with sunitinib (hazard ratio, 0.552; 95% CI, 0.291–1.047; nominal p = .065). PFS on third‐line therapy was comparable between treatment arms in both populations.
Conclusions
After two additional years of follow‐up, ripretinib showed a trend toward clinically meaningful OS benefit versus sunitinib in the Ex11 ITT population. Second‐line ripretinib does not appear to affect third‐line treatment efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Harbin Medical University Cancer Hospital, Harbin, China.
- Sun Yat-sen University Cancer Center, Guangzhou, China.
- The Affiliated Hospital of Qingdao University, Qingdao, China.
- Fujian Medical University Union Hospital, Fuzhou, China.
- The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Haibo Qiu, Yongjian Zhou, Xinhua Zhang, Yuping Zhu, Kaixiong Tao, Zhaolun Cai, Zhidong Gao, Jian Li
Zitieren
APA
Zhang, J., Zhang, Y., Qiu, H., Zhou, Y., Zhou, Y., Zhang, X., Zhou, Y., Zhu, Y., Li, Y., Wang, M., Shen, K., Tao, K., Wu, X., Wang, H., Zhang, B., Ling, J., Ye, Y., Wu, X., Qu, H., …, & Li, J. (2025). Long‐term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial. Cancer. https://doi.org/10.1002/cncr.70150
Vancouver
Zhang J, Zhang Y, Qiu H, Zhou Y, Zhou Y, Zhang X, et al. Long‐term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial. Cancer. 2025. doi:10.1002/cncr.70150
BibTeX
@article{Zhang2025,
author = {Zhang, Jun and Zhang, Yanqiao and Qiu, Haibo and Zhou, Yanbing and Zhou, Yongjian and Zhang, Xinhua and Zhou, Ye and Zhu, Yuping and Li, Yong and Wang, Ming and Shen, Kuntang and Tao, Kaixiong and Wu, Xin and Wang, Haijiang and Zhang, Bo and Ling, Jiayu and Ye, Yingjiang and Wu, Xingye and Qu, Hongyan and Ma, Yue and Jiao, Xuelong and Zheng, Hualong and Jin, Jiejie and Liu, Zhuo and An, Zhaojie and Zhang, Peng and Liu, Peifa and Lei, Cheng and Cai, Zhaolun and Gao, Zhidong and Shen, Lin and Li, Jian},
title = {Long‐term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.70150}
}
EUVIMED